Efficacy of 13.3?mg/24?h versus 4.6?mg/24?h rivastigmine patch on activities of daily living in severe Alzheimer's disease.
Ontology highlight
ABSTRACT: OBJECTIVE:Investigate efficacy of 13.3?mg/24?h rivastigmine patch in patients with severe Alzheimer's disease on Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale-Severe Impairment Version items and domains. METHODS:Retrospective analysis of the 24-week, randomized, double-blind ACTivities of daily living and cognitION (ACTION) study, using factor analysis to establish "best fit" for Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale-Severe Impairment Version items into domains. Treatment differences (13.3 vs 4.6?mg/24?h patch) on items and domains were assessed. RESULTS:Overall, 632 patients provided Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale-Severe Impairment Version data. Factor analysis yielded four domains. The 13.3 versus 4.6?mg/24?h patch demonstrated significantly greater efficacy on "Daily function" (p?=?0.038), supported by greatest effect sizes on items within this domain, and trend toward greater efficacy on "Communication" (p?=?0.052). No significant between-group differences were observed on "Independence" (p?=?0.600) or "Environment" (p?=?0.261). CONCLUSION:The 13.3?mg/24?h patch was superior to 4.6?mg/24?h patch on "Daily function" in severe Alzheimer's disease.
SUBMITTER: Micca JL
PROVIDER: S-EPMC4607239 | biostudies-literature | 2014
REPOSITORIES: biostudies-literature
ACCESS DATA